13 Results

People

  1. Matasar
    Matasar
  2. Rademaker
    Rademaker
  3. Moskowitz
    Moskowitz
  4. Younes
    Younes
  5. Zelenetz
    Zelenetz
  6. Hamlin
    Hamlin
  7. Horwitz
    Horwitz
  8. Kumar
    Kumar
  9. Moskowitz
    Moskowitz
  10. Batlevi
    Batlevi

Groups

  1. Body Imaging Service (13)
  2. Center for Hematologic Malignancies (13)
  3. Department of Medicine (13)
  4. Hematologic Malignancies, Division of (13)
  5. Lymphoma (13)
  6. Radiology, Department of (13)
  7. Survivorship Research (13)
  8. Biostatistics Service (9)
  9. Epidemiology and Biostatistics (9)
  10. Executive Committee, Center for Hematologic Malignancies (8)
  1. "Matthew Matasar"
  2. "Body Imaging Service"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (5)
Groups
  1. Body Imaging Service (13)
  2. Center for Hematologic Malignancies (13)
  3. Department of Medicine (13)
  4. Hematologic Malignancies, Division of (13)
  5. Lymphoma (13)
  6. Radiology, Department of (13)

More Groups

People
  1. Matthew Matasar (13)
  2. Jurgen Rademaker (11)
  3. Alison Moskowitz (8)
  4. Anas Younes (8)
  5. Andrew Zelenetz (8)
  6. Anita Kumar (7)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (5)

More Years

Publications
  1. Hematological Oncology (3)
  2. Journal of Clinical Oncology (3)
  3. Blood (2)
  4. American Journal of Hematology (1)
  5. Clinical Cancer Research (1)
  6. Journal of Cardiovascular Magnetic Resonance (1)

More Publications

Publishers
  1. Wiley Blackwell (4)
  2. American Society of Clinical Oncology (3)
  3. American Society of Hematology (2)
  4. American Association for Cancer Research (1)
  5. Biomed Central Ltd (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer
    Journal Article

    Chan, A. T.; Plodkowski, A. J.; Pun, S. C.; Lakhman, Y.; Halpenny, D. F.; Kim, J.; Goldburg, S. R.; Matasar, M. J.; Moskowitz, C. S.; Gupta, D.; more...
    Journal of Cardiovascular Magnetic Resonance (2017)

    Fulltext@MSK | Save
  • Whole-body diffusion-weighted MR imaging in lymphoma surveillance
    Meeting Abstract

    Rademaker, J.; Ryan, D.; Matasar, M.; Portlock, C.
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save